insights_auto
Outlook: 40.9% bullish·4.5% bearish
Go to analysischevron_right
ALKS:NASDAQ
Alkermes Plc
40,85 $
arrow_upward
+0,15%(+0,060) 1D
40,85 $
0,00% (0,00)
bedtimeAfter hours
Closed: 25 սեպ, 16:00:01 GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
40,94 $
High
41,12 $
Low
40,49 $
Mkt. cap
6,85 մլրդ
Avg. vol.
1,76 մլն
Volume
2,59 մլն
P/E ratio
106,14
52-wk high
55,67 $
52-wk low
27,00 $
EPS
0,38 $
Beta
0,27
Shares outstanding
167,76 մլն
No. of employees
2 հզր
Open
40,94 $
High
41,12 $
Low
40,49 $
Mkt. cap
6,85 մլրդ
Avg. vol.
1,76 մլն
Volume
2,59 մլն
P/E ratio
106,14
52-wk high
55,67 $
52-wk low
27,00 $
EPS
0,38 $
Beta
0,27
Shares outstanding
167,76 մլն
No. of employees
2 հզր
News stories
From web sources and news partners
Seeking Alpha
·
22 ժամ առաջ
Alkermes: Idiopathic Hypersomnia Could Expand LUMRYZ Into A Larger Growth, Margin Driver
Yahoo Finance
·
1 օր առաջ
Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?
Fierce Biotech
·
5 օր առաջ
With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2,05 հզր
Founded1987
Headquarters-
Sector-
Websitealkermes.com